Article Content

Study links daily aspirin use to melanoma risk in men. The risk of malignant melanoma in those undergoing continuous daily aspirin therapy has been unclear. A study published online March 27 in the Journal of the American Academy of Dermatology examines whether that risk could be clarified by comparing patients taking daily aspirin for more than a year with those having no documented aspirin exposure. The researchers found an association between aspirin exposure and subsequent malignant melanoma diagnosis in the large urban population studied; however, after stratifying for sex, the risk was significant only for men. The authors noted two important limitations of the study: the lack of verification of adherence to daily aspirin and no collection of other relevant melanoma risk factors. They recommend further research to explore this association.